Bisphosphonates in the therapy of bone metastases of breast carcinoma
Authors:
J. Chovanec; Z. Dostálová; J. Navrátilová
Authors‘ workplace:
LF MU a FN Brno
; Gynekologicko-porodnická klinika
Published in:
Prakt Gyn 2007; 11(2): 77-80
Overview
Brest cancer is one of the most frequent women cancers, incidence of which is increasing in the whole world. This cancer metastasizes in bones very often. That is why the bones metastases can be the first precursor of this disease. Because of these metastases these women have skeletal complications and the pain is the most dominant. The aim of therapy of bone metastases is to slow down the progression of this disease and to improve the quality of live for these patients. Great progress in this therapy was reached by using of bisphosphonates. Inhibition of osteoclasts activity is one of the most important effects of bisphosphonates. Recently bisphosphonates are divided into three groups. The therapy of bone metastases represents a serious medicine problem. Bisphosphonates therapy should be started immediately after diagnose proof.
Key words:
brest cancer - bone metastases – therapy - bisphosphonates
Sources
1. Chod J. Epidemiologie a rizikové faktory vzniku karcinomu prsu. Mod Gyn Por 2004; 3: 397-403.
2. Novotný J, Pecen L, Petrželka L. Identifikace žen se zvýšeným rizikem vzniku karcinomu prsu. Mod Gyn Por 2004; 3: 439-444.
3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategie. Cancor Treat Rev 2001; 27: 165-176.
4. Jemal A, Tiwari RC, Murray T et al. Cancer statistics. CA Cancer J Clin 2004; 54: 8-29.
5. Coleman RE. Bisphosphonates in Brest cancer. Ann Oncol 2005; 16: 687-695.
6. Vitte C, Fleisch H, Gunther H. Bisphosphonates induce osteoclasts to secrete an inhi-bitor of osteoclast-mediated resorption. Endocrinology 1996; 137: 2324-2333.
7. Fleisch H. Development of bisphosphonates. Brest Cancer Res 2002; 4: 30-34.
8. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibictor of bone resorption. Drug Dev Res 2002; 55: 210-224.
9. Coleman RE. Zoledronic acid for the treatment of malignant bone disease. Eur J Hospital Pharmacy 2004; 1: 129-136.
10. Pavlakis N, Stockler S. Bisphosphonates for Brest cancor (Cochrane Review). The Cochrane Library. Chichester: John Wiley & Sons 2004: 1.
11. Kohno N, Sobi K, Minami H. A randomized, double blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastase from Brest cancor. Proc Am Soc Clin Oncol 2004; 23: 43.
12. Wong R, Wiffen PJ. Bisphosphonates for the reliéf of pain secondary to bone metastase (cochrane Review). The cochrane Lobrary. Chichester: John Wiley & Sons 2004: 1-59.
13. Hillner BE, Ingle JN, Berenson JR et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000; 18: 1378-1391.
14. Lipton A, Demers L, Curley E et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998; 34: 2021-2026.
15. Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002; 29(suppl 21): 33-42.
16. Vinholes JJ, Purohit OP, Abbey ME et al. Relationship between bio-chemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8: 1243-1250.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2007 Issue 2
Most read in this issue
- Cerazette – practical experience
- Psychological and medical aspects of the birth of a dead foetus
- The influence of tibolonee on fibrocystic changes in the mammary gland
- Bisphosphonates in the therapy of bone metastases of breast carcinoma